Progen Pharmaceuticals Ltd. (PGLA)

Oncology Corporate Profile

HQ Location

3 Twin Dolphin Drive, Suite 100
Redwood City, CA 94065

Company Description

Progen Pharmaceuticals is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics.

Website: http://www.progen.com.au/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PG545heparanase inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://www.progen.com.au/

Recent News Headlines

Valeant Gets FDA OK for Anticonstipation Tablets Developed by Progenics

7/20/2016 11:23 am

(NASDAQ/Dow Jones Business News) July 19, 2016 - Valeant Pharmaceuticals International Inc. has received U.S. Food and Drug Administration approval for Relistor tablets to treat opioid-induced constipation for patients with noncancer pain.

Blue Ribbon Panel Announced to Help Guide Vice President Biden’s National Cancer Moonshot Initiative

4/4/2016 12:02 pm

(NCI) Apr 4, 2016 - Today, the National Cancer Institute (NCI), part of the National Institutes of Health, announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer Moonshot Initiative.

Progenics Pharmaceuticals Commences Pivotal Phase 3 Study of PSMA Targeted Imaging Agent 1404 for Prostate Cancer

1/7/2016 11:46 am

(Yahoo! Finance) Jan 7, 2016 - Progenics Pharmaceuticals, Inc. announced today that it has begun enrollment in its pivotal Phase 3 clinical trial evaluating 1404, a small molecule being developed as an imaging agent for prostate cancer.

Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azera

12/4/2015 11:28 am

(NASDAQ) Dec 3, 2015 - Progenics Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2b clinical trial of its ultra-orphan radiotherapeutic candidate Azedra™ for the treatment of malignant or recurrent pheochromocytoma and paraganglioma in accordance with the Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA).

Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

7/28/2015 12:00 pm

(StreetInsider) July 28, 2015 - Progenics Pharmaceuticals, Inc., an oncology company developing innovative ways to target and treat cancer, announced today that the U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma.

Siteman Cancer Center Earns Highest Rating From Federal Cancer Institute

7/8/2015 12:00 pm

(St. Louis Post-Dispatch) July 8, 2015 - Siteman Cancer Center at Barnes-Jewish Hospital has earned the highest quality rating from the federal government’s principal agency for cancer research and training.

Detecting Cancer Cells in Blood Can Give an Early Warning of Treatment Failure

3/24/2015 12:00 pm

(ICR [UK]) Mar 23, 2015 - A blood test that measures the number of cells shed from prostate tumours into the bloodstream can act as an early warning sign that treatment is not working, a major new study shows.

Progenics Pharmaceuticals Presents Positive Phase 2 Data For PSMA ADC in Metastatic Castration-Resistant Prostate Cancer

2/26/2015 12:05 pm

(NASDAQ) Feb 26, 2015 - Progenics Pharmaceuticals, Inc. today announced the presentation of the full results from its Phase 2 clinical study of PSMA ADC in patients with metastatic castration-resistant prostate cancer (mCRPC), including new data from the recently completed chemo-naïve cohort.

NICE Rejects Celgene's Myeloma Drug Imnovid

2/13/2015 10:03 am

(PharmaTimes [UK]) Feb 13, 2015 - Patients with multiple myeloma will not be able to access Celgene’s Imnovid (pomalidomide) on the National Health Service in England after cost-regulators issued a final draft ‘no’ for funding as a third-line treatment.

Phase 2 Data for Progenics' 1404 Imaging Agent Presented at EANM Congress

10/20/2014 11:30 am

(CNNMoney) Oct 20, 2014 - Trial data show 1404 more sensitive than MRI in detecting primary and metastatic prostate cancer; phase 1 and 2 data featured in two oral presentations, selected for highlights lecture.

Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma

9/22/2014 12:00 pm

(CNN Money) Sept 22, 2014 - Progenics Pharmaceuticals, Inc. today presented positive data from a pivotal phase 2 clinical study of Azedra(TM) in an oral presentation at the International Symposium of Pheochromocytoma and Paraganglioma (ISP) in Kyoto, Japan.

Jakafi® (ruxolitinib) Product Label Expanded to Include Overall Survival Data and Additional Safety and Dosing Information

7/28/2014 06:04 am

(Incyte) July 28, 2014 - Incyte Corporation announced today that the U.S. Food & Drug Administration (FDA) has approved supplemental labeling for Jakafi® (ruxolitinib) to include new Kaplan-Meier overall survival curves as well as additional safety and dosing information.

Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

4/24/2014 11:59 am

(Reuters) April 24, 2014 - Progenics Pharmaceuticals, Inc. announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC.

Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

4/24/2014 11:05 am

(Reuters) April 24, 2014 - Progenics Pharmaceuticals, Inc. announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC.

Progenics 1404 Imaging Agent Shows High Accuracy in Detecting Cancer Within the Prostate Gland in Interim Analysis of Phase 2 Study

1/31/2014 11:22 am

(NASDAQ) Jan 30, 2014 - 1404 more accurate than MRI in detecting primary prostate cancer in this study.

Progenics 1404 Imaging Agent Shows High Accuracy in Detecting Cancer Within the Prostate Gland in Interim Analysis of Phase 2 Study

1/31/2014 11:02 am

(NASDAQ) Jan 30, 2014 - 1404 more accurate than MRI in detecting primary prostate cancer in this study.

No ‘Brakes’ — Pitt Study Finds Mechanism for Increased Activity of Oncogene in Head and Neck Cancers

1/7/2014 11:05 am

(UPMC) Jan 6, 2014 - The increased activation of a key oncogene in head and neck cancers could be the result of mutation and dysfunction of regulatory proteins that are supposed to keep the gene, which has the potential to cause cancer, in check, according to a new study led by researchers at the University of Pittsburgh School of Medicine.

Progenics Pharmaceuticals Announces That Data From a Phase I Study of Its 1404 Imaging Agent Has Been Presented at the Society for Urologic Oncology Meeting

12/8/2013 05:25 pm

(NASDAQ) Dec 6, 2013 - Progenics' imaging agent correctly identified the presence of primary prostate cancer in 100% of phase I study subjects; Progenics also announces that topline data from a recently completed phase II trial of 1404 will be presented at ASCO GU in January 2014.

Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Experienced Cohort in Phase II PSMA ADC Clinical Trial in Prostate Cancer

12/8/2013 05:24 pm

(NASDAQ) Dec 6, 2013 - Top-line data in chemotherapy experienced patients to be presented at oncology meeting in January 2014; additional cohort in chemotherapy naive patients has been added to the trial.

Progenics Pharmaceuticals Announces Completion of Enrollment of Chemotherapy Experienced Cohort in Phase II PSMA ADC Clinical Trial in Prostate Cancer

12/8/2013 05:02 pm

(NASDAQ) Dec 6, 2013 - Top-line data in chemotherapy experienced patients to be presented at oncology meeting in January 2014; additional cohort in chemotherapy naive patients has been added to the trial.

Progenics Pharmaceuticals Announces That Data From a Phase I Study of Its 1404 Imaging Agent Has Been Presented at the Society for Urologic Oncology Meeting

12/8/2013 05:02 pm

(NASDAQ) Dec 6, 2013 - Progenics' imaging agent correctly identified the presence of primary prostate cancer in 100% of phase I study subjects; Progenics also announces that topline data from a recently completed phase II trial of 1404 will be presented at ASCO GU in January 2014.

Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytoma

11/25/2013 12:19 pm

(Benzinga) Nov 25, 2013 - Progenics Pharmaceuticals, Inc. today announced that it is resuming a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, Azedra, in patients suffering from pheochromocytomas.

Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytoma

11/25/2013 12:01 pm

(Benzinga) Nov 25, 2013 - Progenics Pharmaceuticals, Inc. today announced that it is resuming a phase 2b clinical study of safety and efficacy of a novel targeted radiotherapy, Azedra, in patients suffering from pheochromocytomas.

Researchers Identify Liver Cancer Progenitor Cells Before Tumors Become Visible

10/11/2013 11:02 am

(UC San Diego Health System) Oct 10, 2013 - For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma (HCC) tumors – the most common form of liver cancer.

New Research Shows High Survival Rates after CRS/HIPEC for Mesothelioma, According to Surviving Mesothelioma

8/19/2013 12:00 pm

(SFGate.com) Aug 19, 2013 - A team of researchers in the surgery department at the Roswell Park Cancer Institute in Buffalo, New York say a cancer treatment that combines surgery and chemotherapy results in “acceptable” rates of complications and death and “should be included” in the multidisciplinary care of patients with malignant peritoneal mesothelioma and other operable abdominal cancers.

U.S. Blood Supply Threatened as Donors Face Iron Losses

7/15/2013 12:01 pm

(Bloomberg) July 15, 2013 - Dennis Gastineau, who happens to be a hematologist, is among the 2.4 million donors who risk silent damage as a result of frequent blood donation.

Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013

6/1/2013 07:18 pm

(NASDAQ) June 1, 2013 - Progenics Pharmaceuticals, Inc. today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Progenics Pharmaceuticals' Data From a Phase 1 Study of PSMA ADC Presented at ASCO 2013

6/1/2013 07:01 pm

(NASDAQ) June 1, 2013 - Progenics Pharmaceuticals, Inc. today reported findings from the phase 1 clinical trial in prostate cancer patients of its PSMA ADC compound at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Progenics Pharmaceuticals Presents Updated Data From Phase 1 Study of PSMA ADC

2/15/2013 10:50 am

(MarketWatch) Feb 14, 2013 - Progenics Pharmaceuticals, Inc. today reported positive clinical data from a completed phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA).

Progenics Acquires Molecular Insight Pharmaceuticals to Expand Oncology-Focused Pipeline

1/22/2013 12:41 pm

(4-traders) Jan 22, 2013 - Progenics Pharmaceuticals, Inc. today announced that it has acquired Molecular Insight Pharmaceuticals, Inc., a clinical-stage private biotechnology company with a small molecule chemistry pipeline aimed at enhancing cancer treatment.

Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients

9/28/2012 12:37 pm

(Yahoo! Finance) Sept 28, 2012 - Progenics Pharmaceuticals, Inc. has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing drug to malignant cells.

Progenics Cuts Jobs, Says CFO McKinney Will Leave

9/21/2012 11:43 am

(CBS News/Associated Press) Sept 20, 2012 - Progenics Pharmaceuticals Inc. said Thursday it has eliminated about a quarter of its staff positions and is cutting back on research to save money.

Sanofi Wins U.S. FDA Approval for Multiple Sclerosis Pill

9/13/2012 12:02 pm

(Bloomberg) Sept 13, 2012 - Sanofi won U.S. backing to sell the multiple sclerosis pill Aubagio, enabling the drugmaker to enter a $12 billion industry, even as analysts said the medicine may be overshadowed by more effective products.

GlaxoSmithKline Buys 5 Million Shares in Response Genetics; Now Owns 15.2%

9/13/2012 12:01 pm

(Fox Business/Dow Jones Newswires) Sept 13, 2012 - GlaxoSmithKline PLC, the pharmaceutical company, announced Thursday that it bought five million newly issued shares of Response Genetics, Inc. at 1.10 dollars per share in cash, meaning that GSK now owns 15.2% of the expanded share capital of RGI.

FDA Approves New Treatment for Severe Neutropenia in Certain Cancer Patients

8/29/2012 04:04 pm

(FDA) Aug 29, 2012 - The U.S. Food and Drug Administration today approved Sicor Biotech’s tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

PCA3 Test Featured at American Urological Association Meeting

5/25/2012 11:00 am

(Yahoo! Finance) May 25, 2012 - DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

FDA Extends Review of Salix, Progenics Drug

4/25/2012 12:03 pm

(CNBC/Associated Press) Apr 25, 2012 - Salix Pharmaceuticals Ltd. and Progenics Pharmaceuticals Inc. said Wednesday the Food and Drug Administration will take an additional three months to consider a new approval for its constipation drug Relistor.

Women Have Higher Death Risk, Less Chest Pain From Heart Attack in Study

2/22/2012 12:01 pm

(Bloomberg) Feb 21, 2012 - Women who are hospitalized for a heart attack are less likely to experience chest pain and are more likely to die than men the same age, researchers said.

Progenics Pharmaceuticals Announces Strategic Focus on Oncology

9/15/2011 12:48 pm

(MarketWatch) Sept. 15, 2011 - Progenics Pharmaceuticals, Inc. today announced strategic, operational, organizational and financial changes resulting from a review of its business.

FDA Advisory Panel For PROGENSA PCA3 Delayed

8/30/2011 09:19 am

(DiagnoCure) Aug 29, 2011 - DiagnoCure, Inc., a life sciences company that develops and commercializes high-value cancer diagnostic tests, announced today that Gen-Probe Incorporated, its commercial partner for the PCA3 test, received notice from the U.S. Food and Drug Administration (FDA) that the PROGENSA® PCA3 Assay will not be reviewed by the Immunology Panel of FDA’s Medical Devices Advisory Committee on October 14, 2011 as previously scheduled, but will be reviewed by the Panel at a later date.

Acquisition of Robotic Technology Leads to Increased Rates of Prostate Cancer Surgery

3/10/2011 12:04 pm

(NYU Langone Medical Center) Mar 10, 2011 - A new study conducted by researchers at NYU Langone Medical Center and Yale School of Medicine shows that when hospitals acquire surgical robotic technology, men in that region are more likely to have prostate cancer surgery.

Progenics Reports Positive Preliminary Data from Ongoing Phase 1 Clinical Study of PSMA ADC

2/18/2011 12:00 am

(TheStreet) Feb 17, 2011 - Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate (ADC) designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen (PSMA).

Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR®

2/7/2011 12:00 am

(Yahoo! Finance) Feb 7, 2011 - Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

Progenics Extends Agreement With Pfizer For RELISTOR Commercialization

9/27/2010 12:00 am

(TheStreet) Sept 27, 2010 - Progenics Pharmaceuticals, Inc. today announced it has extended its agreement with Wyeth (now a subsidiary of Pfizer Inc.) to continue Wyeth’s commercialization of RELISTOR ® (methylnaltrexone bromide) Subcutaneous Injection in the United States through at least December 31, 2010.

Progen Nasdaq Delisting Update (PR Newswire)

7/2/2010 01:52 am

Progen Pharmaceuticals Limited today provided an update relating to the Nasdaq Delisting Notification received on 23 June 2010 advising that its securities would be delisted due to a minimum bid price deficiency under Nasdaq Listing rule 5500 .

Progen Receives Delisting Notification from Nasdaq (PR Newswire)

6/24/2010 03:25 am

Progen Pharmaceuticals Limited today received notice from the Nasdaq Stock Market that its securities will be delisted due to a minimum bid price deficiency under Nasdaq Listing Rule 5500.

Progenics Phase 1 PSMA ADC Study Presented in New "Trials in Progress" Poster Session at ASCO Annual Meeting

6/7/2010 12:00 am

(Yahoo! Finance) June 7, 2010 - Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

KAI Pharmaceuticals Acquires Patents from Progen, Broadening KAI's Intellectual Property Estate Covering Peptide-Based Therapies (Business Wire)

6/30/2009 02:15 pm

SOUTH SAN FRANCISCO, Calif.----KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced today the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Limited , a globally focused biotechnology company.